Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

NCT02411695 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Brexpiprazole (OPC-34712)

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborators

[object Object]